BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16528611)

  • 21. Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain.
    Glover JN
    Fam Cancer; 2006; 5(1):89-93. PubMed ID: 16528612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors.
    Awadelkarim KD; Aceto G; Veschi S; Elhaj A; Morgano A; Mohamedani AA; Eltayeb EA; Abuidris D; Di Gioacchino M; Battista P; Verginelli F; Cama A; Elwali NE; Mariani-Costantini R
    Breast Cancer Res Treat; 2007 Apr; 102(2):189-99. PubMed ID: 17333343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classification of BRCA1 missense variants of unknown clinical significance.
    Phelan CM; Dapic V; Tice B; Favis R; Kwan E; Barany F; Manoukian S; Radice P; van der Luijt RB; van Nesselrooij BP; Chenevix-Trench G; kConFab ; Caldes T; de la Hoya M; Lindquist S; Tavtigian SV; Goldgar D; Borg A; Narod SA; Monteiro AN
    J Med Genet; 2005 Feb; 42(2):138-46. PubMed ID: 15689452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
    Lovelock PK; Healey S; Au W; Sum EY; Tesoriero A; Wong EM; Hinson S; Brinkworth R; Bekessy A; Diez O; Izatt L; Solomon E; Jenkins M; Renard H; Hopper J; Waring P; Tavtigian SV; Goldgar D; Lindeman GJ; Visvader JE; Couch FJ; Henderson BR; Southey M; Chenevix-Trench G; Spurdle AB; Brown MA;
    J Med Genet; 2006 Jan; 43(1):74-83. PubMed ID: 15923272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional assays for BRCA1 and BRCA2.
    Carvalho MA; Couch FJ; Monteiro AN
    Int J Biochem Cell Biol; 2007; 39(2):298-310. PubMed ID: 16978908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
    Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
    Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
    Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
    Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.
    Cortesi L; De Nicolo A; Medici V; Marino M; Turchetti D; Pradella LM; Rossi G; Parisini E; Federico M
    Breast Cancer Res Treat; 2012 Jul; 134(1):435-41. PubMed ID: 22527099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of new point mutations of BRCA1 and BRCA2 in breast cancer patients.
    Bensam M; Hafez E; Awad D; El-Saadani M; Balbaa M
    Biochem Genet; 2014 Feb; 52(1-2):15-28. PubMed ID: 23877192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
    Sekine M; Nagata H; Tsuji S; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Tanaka K;
    Clin Cancer Res; 2001 Oct; 7(10):3144-50. PubMed ID: 11595708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
    Carvalho MA; Marsillac SM; Karchin R; Manoukian S; Grist S; Swaby RF; Urmenyi TP; Rondinelli E; Silva R; Gayol L; Baumbach L; Sutphen R; Pickard-Brzosowicz JL; Nathanson KL; Sali A; Goldgar D; Couch FJ; Radice P; Monteiro AN
    Cancer Res; 2007 Feb; 67(4):1494-501. PubMed ID: 17308087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
    Tudini E; Moghadasi S; Parsons MT; van der Kolk L; van den Ouweland AMW; Niederacher D; Feliubadaló L; Wappenschmidt B; Spurdle AB; Lazaro C
    Breast Cancer Res Treat; 2018 Nov; 172(2):497-503. PubMed ID: 30105462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
    Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
    Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
    Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
    Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling.
    Moghadasi S; Hofland N; Wouts JN; Hogervorst FB; Wijnen JT; Vreeswijk MP; van Asperen CJ
    J Med Genet; 2013 Feb; 50(2):74-9. PubMed ID: 23231788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.